TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review): Review Decision - May 2008

Review of NICE Technology Appraisal Guidance No 91; paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for ovarian cancer (advanced) ? 2nd line

Review Decision

During consultation, the majority of comments received by the Institute agreed with the proposal, to defer the review of the guidance until November 2009.  After consideration of all of the comments, the Institute's Guidance Executive have decided to proceed with the proposal.

Summary of the responses from this consultation.

12 May 2008

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.